Lexeo Therapeutics (LXEO) Other Operating Expenses (2023 - 2026)

Lexeo Therapeutics (LXEO) has 4 years of Other Operating Expenses data on file, last reported at -$4.7 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses rose 62.52% year-over-year to -$4.7 million; the trailing twelve-month figure through Mar 2026 stood at -$12.9 million (up 60.41% YoY), and the FY2025 full-year result was -$37.0 million, down 48.06% from the prior year.
• Other Operating Expenses slipped to -$4.7 million in Q1 2026, from $6.9 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $53.1 million in Q4 2023 to a low of -$12.6 million in Q1 2025.
• A 4-year average of $264300.0 and a median of -$4.5 million in 2024 frame the typical range for Other Operating Expenses.
• Peak annual rise in Other Operating Expenses reached 158.39% in 2025, while the deepest fall reached 209.04% in 2025.
• Tracing LXEO's Other Operating Expenses over 4 years: stood at $53.1 million in 2023, then slumped by 122.21% to -$11.8 million in 2024, then soared by 158.39% to $6.9 million in 2025, then plunged by 168.35% to -$4.7 million in 2026.
• Business Quant data shows LXEO's Other Operating Expenses at -$4.7 million in Q1 2026, $6.9 million in Q4 2025, and -$2.9 million in Q3 2025.